Skip to content
Review Open access

Overcoming melanoma drug resistance: Mechanisms and clinical progress of oncolytic viruses combined with immune checkpoint inhibitors (Review)

Sep 2026 · Oncology Report · Vol 56 · 0 citations · 124 references
Medicine

TL;DR

Emerging clinical evidence and mechanistic insights into OV–ICI synergy are synthesized to inform rational trial design, refine combination strategies, and accelerate the development of precision immuno-oncology approaches.

Abstract

Although immune checkpoint inhibitors (ICIs) have revolutionized the management of advanced melanoma, a major clinical challenge persists: Nearly 50% of patients develop primary or acquired resistance and therefore derive no meaningful clinical benefit. As ICIs are increasingly used in earlier disease settings, including adjuvant and neoadjuvant therapy, the population of patients with ICI-resistant disease continues to grow. For patients whose disease progresses after first-line combined programmed cell death 1 (PD-1) and cytotoxic T-lymphocyte associated protein 4 (CTLA-4) blockade, effective salvage options remain limited, highlighting an urgent unmet medical need. Oncolytic viruses (OVs), which exert antitumor effects through the dual mechanisms of selective tumor cell lysis and immunomodulatory remodeling of the tumor microenvironment, represent a compelling therapeutic strategy for overcoming ICI resistance. Recent clinical and preclinical advances have moved OV–ICI combination regimens from conceptual strategies to clinically evaluable interventions for refractory melanoma. Nevertheless, several translational barriers impede their broader implementation, including interpatient heterogeneity in treatment response, uncertainty regarding the optimal sequencing and dosing of combination therapies, and the lack of validated predictive biomarkers. The present review systematically synthesizes emerging clinical evidence and mechanistic insights into OV–ICI synergy to inform rational trial design, refine combination strategies, and accelerate the development of precision immuno-oncology approaches.

Read PDF

Similar papers

Review Open access Sep 2026

Immune Checkpoint Inhibitors in Cancer Therapy: Clinical Landscape, Resistance Mechanisms, and Therapeutic Innovations

This review examines the evolving landscape of ICI‐based combination therapies, including regimens that combine ICI with chemotherapy, targeted therapy, antibody–drug conjugates, antiangiogenic agents, and radiotherapy, which have expanded first‐line treatment options across multiple solid tumors and, in selected setti...

Qiong-Yue Zhang, Zhi-Lai Qin, Caijuan Guo · 0 citations
Review Sep 2026

Recent Advances in Tumor-Infiltrating Lymphocyte Therapy for Melanoma

Overall, TIL therapy constitutes a rapidly evolving and clinically potent treatment modality for melanoma and covers recent advances for improving therapeutic outcomes, including safety optimization, product optimization, next-generation engineered TILs, and predictive biomarkers.

H. Zeng, Wu-Xuan Mei, Chang-Chun Zeng · 0 citations
Review Open access Sep 2026

Therapeutic Resistance in Melanoma: Molecular Mechanisms and Emerging Pharmaceutical Strategies

Cutaneous melanoma remains a global health challenge. Although BRAF/MEK-targeted therapies and immune checkpoint inhibitors (ICIs) have improved outcomes in advanced disease, durable responses remain difficult to achieve for most patients. Therapeutic resistance represents the central barrier to long-term disease contr...

Nicolas Moussallem, Ali Awada, Roy El Darzi et al. · 0 citations
Review Aug 2026

Overcoming resistance to immune checkpoint inhibitors in cancer: translational mechanisms, dynamic biomarkers, clinically actionable combination strategies, and comparative checkpoint biology

This review integrates the major tumor-intrinsic and tumor-extrinsic mechanisms that drive ICI resistance, including defective antigen presentation, impaired interferon signaling, oncogenic and epigenetic immune escape programs, metabolic rewiring, suppressive myeloid and stromal circuits, abnormal vasculature, and pro...

R. Karataş, Yaren Alras, Sarenur Teki̇ner et al. · 0 citations
Review Open access Sep 2026

NEW IMMUNOTHERAPY STRATEGIES FOR MELANOMA: CHECKPOINT INHIBITORS, COMBINATION THERAPIES AND mRNA VACCINES

Current and emerging treatment approaches based on modulation of the immune response, with particular emphasis on immune checkpoint inhibitors, targeted therapies, and mRNA vaccines are discussed.

Artur Marcysiak, Patrycja Mularczyk, Nina Polek et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.